Drug class

Bone Formation Stimulating Agents - Natriuretic Peptide

"Bone Formation Stimulating Agents - Natriuretic Peptide" is a commercial compendia and formulary classification, rather than a standardized FDA-established drug class, used primarily to categorize C-type natriuretic peptide (CNP) analogs such as vosoritide. Read more about Bone Formation Stimulating Agents - Natriuretic Peptide

2 drugs in this class 2 manufacturers

Advertisement

Drugs in Bone Formation Stimulating Agents - Natriuretic Peptide

Showing 1–2 of 2 drugs

VOXZOGO (vosoritide)

BONE FORMATION STIMULATING AGENTS - NATRIURETIC PEPTIDE · GROWTH FAILURE DUE TO ACHONDROPLASIA
BIOMARIN PHARMA

YUVIWEL (navepegritide)

BONE FORMATION STIMULATING AGENTS - NATRIURETIC PEPTIDE · GROWTH FAILURE DUE TO ACHONDROPLASIA
ASCENDIS PHARMA
Filter & compare in the drug finder → Opens the drug finder with Bone Formation Stimulating Agents - Natriuretic Peptide preselected. Add indication or manufacturer filters there.

About Bone Formation Stimulating Agents - Natriuretic Peptide.

"Bone Formation Stimulating Agents - Natriuretic Peptide" is a commercial compendia and formulary classification, rather than a standardized FDA-established drug class, used primarily to categorize C-type natriuretic peptide (CNP) analogs such as vosoritide.

These therapeutic agents act by binding directly to the natriuretic peptide receptor-B (NPR-B), which inhibits the downstream MAPK/ERK pathway to stimulate endochondral bone growth and chondrocyte proliferation.

Clinically, this category is indicated to promote linear growth in pediatric patients with achondroplasia who have open epiphyses.